IBIS-Virgen del Rocío University Hospital (IBiS-HUVR) and IDIBELL are two Government-designated Healthcare Research
Institutes with a sarcoma program. In addition, IBiS-HUVR has recently been accredited by the Ministry of Health as one out of
two National Reference Centers for diagnosis and treatment of pediatric sarcomas (CSUR). Complementarity with the ongoing
research stems from previous contributions of this group to this area/topic, which are mainly shown in the document “Scientific
and Technological Profile CIBER”. We would like to highlight that our group, which emcompasses both Institutes, has made
significant contributions on the identification and clinical validation of several relevant Precision Medicine biomarkers drugs/targets, with focus on Immunotherapy biomarkers, and in Ewing sarcoma, such as
CAV1, NEDD-8 inhibitors, IGF1R inhibitors, PARP1 inhibitors, mTOR inhibitors, CDK inhibitors, which is fully consistent with
the CIBER topic we are applying to. Combined treatments of these targeted therapies with standard chemotherapy are also
explored. Furthermore, our group has contributed significantly to the understanding of the clues related to the progression of
these aggressive tumors. In addition, the contributions of our group to the definition of clinical guidelines in Ewing sarcoma
should be emphasized. We have published over 50 manuscripts on Ewing sarcoma in the last 10 years, 90% of them in the first
quartile. Many of these manuscript
